October 17, 2023
Company Description: Degron Therapeutics is a preclinical-stage biotech dedicated to the discovery and development of a new class of targeted protein degradation therapeutics – small molecule molecular glue degrader (MGD) drugs, bringing solutions to disease targets that are undruggable by conventional small molecule inhibitors. Degron Therapeutics has built a unique molecular glue library with different core structures from those of IMiDs, allowing it to explore new chemical space and differentiated targets. Furthermore, the company has established a scientifically robust molecular glue Mechanism of Action (MOA) validation system, unlocking the potential to address challenging drug targets. This cutting-edge platform provides invaluable insights into the mechanisms behind molecular glue drugs, enabling the discovery of novel MGD drugs for previously undruggable disease targets.
United State of America
CEO/Top Company Official
Lead Product in Development
Degron’s lead program targets an undruggable RNA binding protein that regulates important oncology pathways. It is FIC and being developed for multiple oncology indications with high unmet need.
Development Phase of Primary Product
Number Of Unlicensed Products